eClinicalMedicine:重磅!张国福团队发现罂粟乙碘油造影剂在子宫输卵管造影中更优

2022-08-29 复旦大学附属妇产科医院 复旦大学附属妇产科医院

在HSG检查中,罂粟乙碘油造影剂在提高影像质量和增强生育能力的疗效优于碘水造影剂。

近日,国际知名杂志《eClinicalMedicine》(IF=17.033,JCR 1区)刊登了复旦大学附属妇产科医院张国福主任团队参与的多中心临床研究的最新成果。该研究为评价罂粟乙碘油造影剂用于不孕人群子宫输卵管造影的影像诊断质量和助孕作用的随机、对照、多中心研究,共15个医疗中心参与此项研究,大家均有相同一致的贡献。

罂粟乙碘油造影剂对子宫输卵管造影(HSG)图像质量的提高和增强生育能力的疗效已有国外的研究证实,但在中国人口中是否有类似的影响尚不清楚。在2017年7月18日至2019年12月29日间,有15个医疗中心共同参与进行了多中心、随机、对照的临床试验。符合子宫输卵管造影指征的不孕妇女被随机分配到碘油组和碘水组。主要分析内容包括子宫输卵管造影的图像质量和增强生育能力的疗效。共有1026名受试者被随机分为碘油组(N = 508)和碘水组(N = 518)。

最终,分析HSG图像质量显示,碘油组具有出色的图像质量(均P < 0.001),包括子宫轮廓、输卵管轮廓、输卵管弥散、腹腔分布和诊断质量,评分均比碘水组高。在提高生育能力的评价中,碘油组的怀孕人数也明显增多,术后至怀孕时间明显比碘水组缩短 (均P < 0.01)。在不良事件方面,碘油组子宫输卵管造影后腹痛和阴道出血的发生率较低 (均P < 0.01)。

在HSG检查中,罂粟乙碘油造影剂在提高影像质量和增强生育能力的疗效优于碘水造影剂。本研究提示了在不孕病人子宫输卵管造影中应优先使用罂粟乙碘油造影剂,为子宫输卵管造影的造影剂选择提供了详尽的评价和严谨的数据分析,对于临床和影像医师能给予有力的指导。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-12-25 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-09-10 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 zll0628
  6. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 xxxx1054
  7. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1774091, encodeId=a0c91e740917e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Dec 25 06:30:06 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924656, encodeId=de2c19246561e, content=<a href='/topic/show?id=ecbc93e6143' target=_blank style='color:#2F92EE;'>#输卵管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93761, encryptionId=ecbc93e6143, topicName=输卵管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Wed Nov 09 16:30:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859297, encodeId=79d2185929ede, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Sep 10 10:30:06 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494219, encodeId=073c149421962, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507860, encodeId=28ad150e8601b, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549872, encodeId=dba015498e207, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577923, encodeId=35cd15e79232d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611713, encodeId=8dbd1611e1332, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 31 01:30:06 CST 2022, time=2022-08-31, status=1, ipAttribution=)]

相关资讯

J Pathol:中国人群甲状腺乳头状癌遗传图谱绘就

近日,中国科学院北京生命科学研究院孙中生研究团队与北京大学肿瘤医院头颈外科刘宝国课题组合作,收集了355对甲状腺乳头状癌的癌组织和癌旁组织样本,运用目标区域扩增子测序技术和RNA目标区域捕获测序技术对癌症样本中的点突变和基因融合作了全面检测,绘制了中国人群甲状腺乳头状癌的遗传图谱。相关研究成果发表在《病理学杂志》上。

Prostate Cancer P D:中国人口中激素敏感性前列腺癌患者的TP53变异情况

前列腺癌(PCa)在临床和基因组特征上表现出了种族差异,亚洲PCa患者在诊断时往往表现出更具侵袭性的表型。TP53作为PCa预后生物标志物的表现在西方人群中已经有了充分的研究。然而,还没有研究调查TP

Clinica Chimica Acta:中国人群中与血心肌肌钙蛋白I浓度相关的生物学和时间因素

心肌肌钙蛋白是诊断急性心肌梗死的基础生物标志物。

JCEM:中国人群中血脂与2型糖尿病的风险及流行有何关联?

Yonghai Lu等人之前通过一个不相关分析报道了在中国人群中溶血磷脂酰肌醇(LPI)(16:1)和2型糖尿病风险之间的关系。而近日其在JCEM上发表的文章则是旨在明确LPIs及其相关代谢产物,比如非酯化脂肪酸(NEFAs)和酰基肉碱,与2型糖尿病发病率和患病率之间所有的关联。

CheckMate-078研究:首次印证免疫治疗在中国人群的疗效和安全性

CheckMate-078研究是第一项针对东亚人群,特别以中国人群为主的免疫检查点抑制剂二线治疗晚期NSCLC的临床研究。与纳武利尤单抗(Nivolumab)在全球注册临床CheckMate-017研究和CheckMate-057研究结果一致,在CheckMate-078研究中,纳武利尤单抗对比化疗显著降低患者的死亡风险。该研究成功的进一步验证了纳武利尤单抗的卓越疗效和安全性。基于CheckMat

PNAS:中国人的阿尔兹海默症新基因风险位点!这三个基因都和AD相关

阿尔兹海默症(AD)是和年龄相关的神经退行性疾病。中国AD患者人数在近期已经跃居世界第一,预计到2050年,中国AD患者将超过2000万。而在昨日,PNAS报道了和中国人相关的AD基因图谱,明确了基因同免疫系统在AD进展中的作用。